IMPORTANT SAFETY INFORMATION WARNING:
Life-threatening allergic reactions have occurred in some patients during VIMIZIM® (elosulfase alfa) infusions and up to 3 hours after infusion. Patients with acute respiratory illness may be at increased risk and require additional monitoring.
Approved by the Food and Drug Administration (FDA) in 2014, VIMIZIM® (elosulfase alfa) allows clinicians —for the first time—to go beyond palliative care and address the systemic enzyme deficiency seen in patients with Morquio A.1,2
VIMIZIM® (elosulfase alfa) significantly improves endurance as demonstrated by improved performance on the 6MWT (P=0.0174) in the largest interventional trial of ERT in any mucopolysaccharidosis (MPS) disease.1,3